Have over 27 years’ experience in clinical trials management. Prior to joining V-Wave medical as Director of Clinical Affairs i worked at PolyPid as Senior Clinical Development for 1.5 years and worked for 12 years at Medinol Ltd., where i was responsible for leading the operations of the company’s coronary/peripheral/drug-eluting stenting clinical trials. I have also managed various clinical trials at Bristol Myers Squibb (BMS) and Bayer pharmaceutical companies. I hold RN and medical administration degrees from Tel-Aviv University, and an MBA from Herriot-Watt University, Edinburgh Business School.
Nadeeka is a neuroscientist and digital health outcomes expert with in-depth experience consulting on pre- and post-approval clinical trials. At ERT, Dr. Dias provides scientific and technology guidance to global sponsors on electronic clinical outcome assessments (eCOA) across several therapeutic areas. In addition to leading the ERT Science team in thought leadership strategy, her expertise extends to eCOA regulatory guidance, instrument development and validation, and eCOA product/software design. She has presented numerous abstracts at global conferences and published several articles on the patient perspective in clinical trials. Prior to joining ERT, Dr. Dias conducted clinical research at Harvard Medical School.
A courageous Quality Leader with lots of broad experience and the ability to motivate people at the team and individual level.
An Innovative, “out of the box” thinker with excellent communication skills.
Expert in Global Discipline Entrepreneurship & Global Innovation
From my educational background I am biologist. I have completed my PhD at the Helmholtz Research Centre of Munich in cooperation with the Technical University of Munich in the field of toxicology.
After that I gained several years of experience in the pharmaceutical industry with a focus on quality management.
Since nearly 4 years, I am working within TÜV SÜD in the sector of Medical Health Services. Currently, I am leading a team of experts and auditors for non-active medical devices and I am responsible for the Article 117 business in the regions DACH & Nordics.
Besides these roles, I am Auditor and Senior Product Specialist for non-active medical devices.
He is the founder and former CEO of Trials24, a company supporting biotech and pharmaceutical companies, as well as CROs, in accelerating patient recruitment. Trials24 was acquired by SubjectWell in September 2024 prior to its merger with Clariness.
Before founding Trials24, Tobias co-founded ImevaX, a biotech company focused on vaccine development, where he developed the entire digital patient recruitment strategy.
Tobias earned his PhD in Molecular Biotechnology from the Technical University of Munich, where he developed a vaccine against Helicobacter pylori. He holds numerous patents and has published papers in journals such as Nature and EMBO.